WXXWY OTC
Credit Risk of going bust: lower than 86% of companies Debt: 1.7% of company value Bonds: none of note held by US funds details ▾
Total debt $409.7M against a stock market value of $23.52B.
Distance to default 11.69 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $130.2M (short-term plus half of long-term), stock volatility 44.3%; Altman Z'' 7.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Wuxi, JS 214092
CN
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc.
-inc-logo-1200x675.png){kind=logo}
